E Martina Bebin

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2540214/publications.pdf

Version: 2024-02-01

41 papers	2,032 citations	331670 21 h-index	302126 39 g-index
41 all docs	41 docs citations	41 times ranked	3563 citing authors

#	Article	IF	Citations
1	Disruption of MeCP2â€“TCF20 complex underlies distinct neurodevelopmental disorders. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	15
2	Inherited variants in CHD3 show variable expressivity in Snijders Blok-Campeau syndrome. Genetics in Medicine, 2022, 24, 1283-1296.	2.4	9
3	Tuber Locations Associated with Infantile Spasms Map to a Common Brain Network. Annals of Neurology, 2021, 89, 726-739.	5.3	24
4	Long-read genome sequencing for the molecular diagnosis of neurodevelopmental disorders. Human Genetics and Genomics Advances, 2021, 2, 100023.	1.7	20
5	Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy. Epilepsy and Behavior, 2021, 117, 107862.	1.7	27
6	Variants in the degron of AFF3 are associated with intellectual disability, mesomelic dysplasia, horseshoe kidney, and epileptic encephalopathy. American Journal of Human Genetics, 2021, 108, 857-873.	6.2	19
7	Pharmacogenetic Predictors of Cannabidiol Response and Tolerability in Treatmentâ€Resistant Epilepsy. Clinical Pharmacology and Therapeutics, 2021, 110, 1368-1380.	4.7	22
8	Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 2021, 123, 50-66.	2.1	230
9	Epilepsy Is Heterogeneous in Early-Life Tuberous Sclerosis Complex. Pediatric Neurology, 2021, 123, 1-9.	2.1	5
10	Profile of Autism Spectrum Disorder in Tuberous Sclerosis Complex: Results from a Longitudinal, Prospective, Multisite Study. Annals of Neurology, 2021, 90, 874-886.	5.3	13
11	EEG Spectral Features in Sleep of Autism Spectrum Disorders in Children with Tuberous Sclerosis Complex. Journal of Autism and Developmental Disorders, 2020, 50, 916-923.	2.7	2
12	Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy. Epilepsy and Behavior, 2020, 111, 107299.	1.7	24
13	Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy. Epilepsy and Behavior, 2020, 112, 107297.	1.7	17
14	Effects of highly purified cannabidiol (CBD) on fMRI of working memory in treatment-resistant epilepsy. Epilepsy and Behavior, 2020, 112, 107358.	1.7	10
15	Fibulin-5 mutation featuring Charcot-Marie-Tooth disease, joint hyperlaxity, and scoliosis. Neurology: Genetics, 2020, 6, e476.	1.9	0
16	Epilepsy and Electroencephalographic Abnormalities in SATB2-Associated Syndrome. Pediatric Neurology, 2020, 112, 94-100.	2.1	10
17	Pilot Study of Neurodevelopmental Impact of Early Epilepsy Surgery in Tuberous Sclerosis Complex. Pediatric Neurology, 2020, 109, 39-46.	2.1	23
18	Reproducibility of Structural and Diffusion Tensor Imaging in the TACERN Multi-Center Study. Frontiers in Integrative Neuroscience, 2019, 13, 24.	2.1	32

#	Article	IF	Citations
19	Drugâ€“drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Epilepsy and Behavior, 2019, 98, 201-206.	1.7	34
20	Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy. Epilepsy and Behavior, 2019, 97, 105-110.	1.7	34
21	fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy. Epilepsy and Behavior, 2019, 96, 114-121.	1.7	30
22	Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy. Epilepsy and Behavior, 2019, 95, 10-17.	1.7	29
23	Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol. Epilepsy and Behavior, 2019, 95, 131-136.	1.7	35
24	Deleterious Variation in BRSK2 Associates with a Neurodevelopmental Disorder. American Journal of Human Genetics, 2019, 104, 701-708.	6.2	19
25	Early white matter development is abnormal in tuberous sclerosis complex patients who develop autism spectrum disorder. Journal of Neurodevelopmental Disorders, 2019, 11, 36.	3.1	32
26	Visual and semi-automatic non-invasive detection of interictal fast ripples: A potential biomarker of epilepsy in children with tuberous sclerosis complex. Clinical Neurophysiology, 2018, 129, 1458-1466.	1.5	46
27	Natural history and genotypeâ€phenotype correlations in 72 individuals with SATB2â€associated syndrome. American Journal of Medical Genetics, Part A, 2018, 176, 925-935.	1.2	57
28	Cover Image, Volume 176A, Number 4, April 2018. American Journal of Medical Genetics, Part A, 2018, 176, .	1.2	0
29	NBEA: Developmental disease gene with early generalized epilepsy phenotypes. Annals of Neurology, 2018, 84, 788-795.	5.3	44
30	High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex. Epilepsy Research, 2018, 148, 1-7.	1.6	25
31	Social correlates of health status, quality of life, and mood states in patients treated with cannabidiol for epilepsy. Epilepsy and Behavior, 2017, 70, 364-369.	1.7	15
32	Mutations in EBF3 Disturb Transcriptional Profiles and Cause Intellectual Disability, Ataxia, and Facial Dysmorphism. American Journal of Human Genetics, 2017, 100, 117-127.	6.2	62
33	The use of cannabidiol for seizure management in patients with brain tumor-related epilepsy. Neurocase, 2017, 23, 287-291.	0.6	20
34	High Rate of Recurrent De Novo Mutations in Developmental and Epileptic Encephalopathies. American Journal of Human Genetics, 2017, 101, 664-685.	6.2	337
35	Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia, 2017, 58, 1586-1592.	5.1	267
36	Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants. Pediatrics, 2017, 140, .	2.1	90

#	Article	IF	Citations
37	Eliciting preferences on secondary findings: the Preferences Instrument for Genomic Secondary Results. Genetics in Medicine, 2017, 19, 337-344.	2.4	36
38	MYT1L mutations cause intellectual disability and variable obesity by dysregulating gene expression and development of the neuroendocrine hypothalamus. PLoS Genetics, 2017, 13, e1006957.	3.5	60
39	De novo FGF12 mutation in 2 patients with neonatal-onset epilepsy. Neurology: Genetics, 2016, 2, e120.	1.9	29
40	Clinical Electroencephalographic Biomarker for Impending Epilepsy in Asymptomatic Tuberous Sclerosis Complex Infants. Pediatric Neurology, 2016, 54, 29-34.	2.1	93
41	Cannabis, cannabidiol, and epilepsy â€" From receptors to clinical response. Epilepsy and Behavior, 2014, 41, 277-282.	1.7	136